Pathway Under the FDA’s 505(b)(2) regulatory pa
Post# of 72435
Under the FDA’s 505(b)(2) regulatory pathway, a drug’s road to market approval can be significantly shortened and at much reduced costs. Often only one pivotal Phase 3 study, enrolling a smaller number of patients than is typical, may be required. As well, the drug is eligible for up to five years of market exclusivity post-approval. For more information about the FDA’s 505(b)(2) program, please visit: http://www.fda.gov/downloads/Drugs/…/Guidan...079345.pdf
- See more at: http://cellceutix.com/cellceutix-provides-add...2ttAB.dpuf
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)